Fighting COVID-19 with milk?

As the COVID-19 pandemic continues to claim lives around the world, dairy scientists may have a surprising role to play. In a new report published in the Journal of Dairy Science®, scientists from the University of Michigan (Ann Arbor, MI, USA) and Glanbia PLC Research and Development (Twin Falls, ID, USA) have collaborated to investigate the antiviral properties of cow milk protein against variants of SARS-CoV-2, the virus behind the illness.

The protein in question is lactoferrin, found in the milk of most mammals. Bovine lactoferrin, from cow milk, has bioactive characteristics against many microbes, viruses, and other pathogens and has been found to inhibit SARS-CoV-2 infection under experimental conditions by blocking the ability of the virus to enter target cells, as well as by supporting cells’ antiviral defense mechanisms.

"Bovine lactoferrin has shown antiviral activity in human clinical trials," says lead investigator Jonathan Sexton, PhD, of the University of Michigan Department of Internal Medicine. "For example, orally administered bovine lactoferrin has been shown to improve the severity of viral infections, including rotavirus and norovirus. Given the broad antiviral efficacy and safety, minimal side effects, and commercial availability of bovine lactoferrin, several review papers have suggested using it as a preventive or post-exposure treatment for SARS-CoV-2 infection."

With the goal of improving clinical relevance and translatability, the team tested bovine lactoferrin against some of the most common SARS-CoV-2 variants of concern from around the world, including the WA1 variant representative of the United States outbreak in 2020, the B.1.1.7, B.1.351, and P.1 variants, and the Delta variant. Sexton explains, "Each of these variants includes modifications to the SARS-Cov-2 spike protein that reduce the efficacy of newly produced vaccines. Furthermore, each of these strains shows reduced neutralization by vaccination sera."

The team's aims for this study were to expand upon the observation of the potent in vitro anti-SARS-CoV-2 efficacy that bovine lactoferrin has demonstrated with a more thorough examination, as well as to screen commercially available milk products for antiviral activities, which may be enhanced by the presence of other ingredients in addition to lactoferrin. Finally, they investigated whether dextrose and sorbitol, commonly used in the manufacture of tablets for oral medications, would interfere with the ability of bovine lactoferrin to inhibit SARS-CoV-2.

The researchers found that bovine lactoferrin was effective against all the strains that were tested in vitro, and they expect it would also have activity against additional emergent strains. The other components in commercial milk products did not appear to offer antiviral protection, confirming that that the efficacy of these products does appear to be entirely dependent on bovine lactoferrin. Moreover, the team found that dextrose and sorbitol did not reduce bovine lactoferrin’s effectiveness against SARS-CoV-2 - suggesting the feasibility of developing an anti-COVID pill.

A key benefit of the broad antiviral efficacy of lactoferrin is its potential for the prevention or treatment of emerging diseases. Sexton emphasizes, "This is especially important when there are limited treatment options, or when the treatment options are too costly for widespread use. An orally available therapeutic that covers emerging strains would be ideal for treating SARS-CoV-2 in areas without widespread vaccination or if new strains escape the vaccine."

Although future work is needed to fully understand the antiviral potential for bovine lactoferrin in a clinical setting, this in vitro study represents promise for another tactic in the fight against the global COVID-19 pandemic.

Wotring JW, Fursmidt R, Ward L, Sexton JZ.
Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern.
J Dairy Sci. 2022 Feb 24:S0022-0302(22)00115-1. doi: 10.3168/jds.2021-21247

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...